TherApeutics in Early ProState Cancer (TAPS02)
Targeted Drug Intervention in Men at Risk of Progression on Active Surveillance for Early Prostate Cancer: A Randomised Trial - Therapeutics in Active Prostate Cancer Surveillance (TAPS02).
Sponsor: Cambridge University Hospitals NHS Foundation Trust
This PHASE2 trial investigates Prostate Cancer and is currently actively recruiting participants. Cambridge University Hospitals NHS Foundation Trust leads this study, which shows 9 recorded versions since 2023 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Recruiting PHASE2
-
Jul 2025 — Sep 2025 [monthly]
Recruiting PHASE2
Phase: PHASE3 → PHASE2
-
Nov 2024 — Jul 2025 [monthly]
Recruiting PHASE3
-
Sep 2024 — Nov 2024 [monthly]
Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE3
▶ Show 4 earlier versions
-
Feb 2024 — Jul 2024 [monthly]
Recruiting PHASE3
-
May 2023 — Feb 2024 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Sep 2022 — May 2023 [monthly]
Not Yet Recruiting PHASE3
-
Feb 2022 — Sep 2022 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Cambridge University Hospitals NHS Foundation Trust
- Janssen-Cilag Ltd.
- University of Cambridge
For direct contact, visit the study record on ClinicalTrials.gov .